Ilze Strumfa

Riga Stradiņš University

Professor, MD, Ph.D. Ilze Strumfa is an outstanding medical lecturer, actively involved in the research in pathology. She graduated from the Medical Academy of Latvia with distinction (1998), underwent board certification in pathology (2001) and received a Ph.D. degree in 2005. Currently, she holds the positions of professor and head of the Department of Pathology in the Riga Stradins University (RSU), Latvia. Her 10 years of teaching experience have culminated with the Annual Award (2018) of RSU to the most distinguished teacher 'Lecturer of the Year”. As the Head of the Department of Pathology, she is leading a skilled, motivated team of teachers and scientists that have won the awards of the Best academic unit (2011); Best Ph.D. student (2012) and Best digital junior teacher (2016). I. Strumfa is an author/ co-author of more than 80 peer-reviewed journal articles and 16 chapters in scientific monographs and medical textbooks. I. Strumfa has been the leading expert in several European and national research projects devoted to the development of diagnostic technologies; neuroendocrine and endocrine tumors; breast cancer; laboratory training in research; and tumor microenvironment. Her main research interests include morphological and molecular diagnostics and prognostic assessment of tumors; as well as digital pathology and other innovations in pathology and cytology.

1books edited

12chapters authored

Latest work with IntechOpen by Ilze Strumfa

Reliable diagnosis is the cornerstone, starting point, and prerequisite of successful treatment. Therefore, development of innovative diagnostic technologies represents a hot topic in medical research. Liquid biopsy is a novel, minimally invasive laboratory evaluation concept for diagnostic, prognostic, and predictive testing, as well as dynamic monitoring of treatment or disease course. To achieve these goals, a multitude of specific, targeted tests can be performed to detect free nucleic acids, exosomes, microRNAs, tumor-educated platelets, and whole cells of tumor or fetal origin in different biological fluids, including blood, urine, cerebrospinal fluid, and others. Although tissue biopsy has long been considered the gold standard of diagnostics, especially regarding malignant tumors, liquid biopsy has the advantages of a non-invasive approach and thus low risk of complications. It is technically feasible even in serious general status or if tumors or metastases are not easily accessible using conventional tissue biopsy. The testing is fast, exact, and can be repeated to ensure real-time follow-up. In contrast to classic tumor markers, liquid biopsy is distinguished by high specificity at genomic, proteomic, and cellular levels. It is expected to equal and exceed the diagnostic value of tissue biopsy. The field of liquid biopsies is developing rapidly regarding the selection of targets, technological improvements, and quality assessment. This book, written by a global team of recognized scientists, comprises state-of-the-art reviews on the current knowledge and advances in the technologies and software for liquid biopsy. Examples of practical application of liquid biopsy to evaluate thyroid cancer, multiple myeloma, etc. are discussed as well. The book is intended to serve as a reference for scientists and clinicians interested in the development and practical implementation of liquid biopsy.

Go to the book